Some neutralizing antibodies against SARS-CoV-2 may heighten lung tissue damage from COVID-19, an A*STAR study finds.
Using a large-scale siRNA screen and CRISPR-Cas9 technology, researchers have pinpointed genes that can enhance antibody production in Chinese hamster ovary cells.
Using flow cytometry, researchers have developed a sensitive and specific test for COVID-19 that can identify asymptomatic carriers.
A multifaceted study by the Singapore 2019 Novel Coronavirus Outbreak Research team is filling in some of the gaps left in the urgent quest to understand COVID-19 infection.
A new test manufactured by A*STAR’s Diagnostics Development Hub in partnership with Duke-NUS Medical School could reveal if an individual is likely immune to COVID-19.
A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.
Understanding how closely related coronaviruses circulate seasonally could impact the timing of vaccination against SARS-CoV-2.
Two linear peptides identified by A*STAR researchers on the SARS-CoV-2 spike protein may improve the specificity of serological assays and show potential as vaccine candidates.
A better understanding of the way sugar units are attached to the surface proteins of cancer cells may help to improve targeted cancer treatments, A*STAR scientists say.
By taking advantage of the body’s
natural diversity, antibody drugs can be made less toxic by having a more localized
light chain subunits of therapeutic antibodies impact drug performance and yield